2seventy bio (TSVT) to Release Earnings on Wednesday

2seventy bio (NASDAQ:TSVT) will be posting its quarterly earnings results before the market opens on Wednesday, August 7th. Analysts expect 2seventy bio to post earnings of ($0.34) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

2seventy bio (NASDAQ:TSVT) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). 2seventy bio had a negative return on equity of 67.59% and a negative net margin of 313.51%. The business had revenue of $12.44 million for the quarter, compared to analyst estimates of $11.93 million. On average, analysts expect 2seventy bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

2seventy bio Stock Performance

Shares of TSVT stock traded down $0.06 during mid-day trading on Tuesday, reaching $3.99. The company’s stock had a trading volume of 282,960 shares, compared to its average volume of 975,194. The firm’s 50-day moving average is $4.21 and its two-hundred day moving average is $4.63. The company has a market cap of $205.11 million, a P/E ratio of -0.91 and a beta of 1.77. 2seventy bio has a 1-year low of $1.53 and a 1-year high of $6.79.

Analyst Ratings Changes

A number of research analysts have commented on TSVT shares. Wedbush restated a “neutral” rating and set a $5.00 price target on shares of 2seventy bio in a research note on Thursday, June 27th. The Goldman Sachs Group downgraded 2seventy bio from a “neutral” rating to a “sell” rating and cut their target price for the stock from $5.00 to $2.00 in a research report on Thursday, June 6th. Canaccord Genuity Group upgraded 2seventy bio to a “strong-buy” rating in a research report on Thursday, May 9th. Canaccord Genuity Group cut their price objective on 2seventy bio from $12.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Finally, Citigroup upped their target price on shares of 2seventy bio from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, April 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.43.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.